Menopausal hormone therapy use in 17 European countries during the last decade.

[1]  M. Paesmans,et al.  Systematic review about breast cancer incidence in relation to hormone replacement therapy use , 2014, Climacteric : the journal of the International Menopause Society.

[2]  M. Dibonaventura,et al.  Burden of vasomotor symptoms in France, Germany, Italy, Spain, and the United Kingdom , 2013, International journal of women's health.

[3]  J. Vandromme,et al.  Postmenopausal hormone therapy: risks and benefits , 2013, Nature Reviews Endocrinology.

[4]  M. Paesmans,et al.  Update of the evolution of breast cancer incidence in relation to hormone replacement therapy use in Belgium. , 2012, Maturitas.

[5]  J. Manson,et al.  Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. , 2012, The Lancet. Oncology.

[6]  R. Nappi,et al.  Vaginal Health: Insights, Views & Attitudes (VIVA) – results from an international survey , 2012, Climacteric : the journal of the International Menopause Society.

[7]  E. Grant.  Re: Breast cancer risk in relation to the interval between menopause and starting hormone therapy. , 2011, Journal of the National Cancer Institute.

[8]  J. Manson,et al.  Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. , 2011, JAMA.

[9]  V. Beral,et al.  Breast Cancer Risk in Relation to the Interval Between Menopause and Starting Hormone Therapy , 2011, Journal of the National Cancer Institute.

[10]  N. Panay,et al.  Recommendations for the management of postmenopausal vaginal atrophy , 2010, Climacteric : the journal of the International Menopause Society.

[11]  H. Morrison,et al.  Breast cancer incidence and hormone replacement therapy in Canada. , 2010, Journal of the National Cancer Institute.

[12]  F. Clavel-Chapelon,et al.  Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Beckmann,et al.  Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. , 2009, The Lancet. Oncology.

[14]  S. Cummings,et al.  The effects of tibolone in older postmenopausal women. , 2008, The New England journal of medicine.

[15]  Robert N Hoover,et al.  Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. , 2007, Journal of the National Cancer Institute.

[16]  E. John,et al.  Recent changes in breast cancer incidence and risk factor prevalence in San Francisco Bay area and California women: 1988 to 2004 , 2007, Breast Cancer Research.

[17]  A. Robbins,et al.  Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Michael J Thun,et al.  Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women , 2007, Breast Cancer Research.

[19]  Eric J Feuer,et al.  The decrease in breast-cancer incidence in 2003 in the United States. , 2007, The New England journal of medicine.

[20]  Garnet L Anderson,et al.  Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. , 2006, JAMA.

[21]  A. Genazzani,et al.  The European Menopause Survey 2005: Women's perceptions on the menopause and postmenopausal hormone therapy , 2006, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[22]  Kari Kuulasmaa,et al.  Use of oral contraceptives and hormone replacement therapy in the WHO MONICA project. , 2004, Maturitas.

[23]  S. Rozenberg,et al.  Issues to debate on the Women's Health Initiative (WHI) study. Prescription attitudes among Belgian gynaecologists after premature discontinuation of the WHI study. , 2003, Human reproduction.

[24]  Valerie Beral,et al.  Breast cancer and hormone-replacement therapy in the Million Women Study , 2003, The Lancet.

[25]  M. Koppán,et al.  Issues to debate on the Women's Health Initiative: estrogen: an instrument or the conductor of the orchestra? , 2003, Human reproduction.

[26]  J. Cline,et al.  Effects of tibolone and hormone replacement therapy on the breast of cynomolgus monkeys , 2002, Menopause.

[27]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[28]  P. Remington,et al.  Prevalence and treatment of menopausal symptoms among breast cancer survivors. , 2002, Journal of pain and symptom management.

[29]  P. Franciscis,et al.  Effects of different types of hormone replacement therapy on mammographic density. , 2001, Maturitas.